论文部分内容阅读
目的：探讨多药耐药相关蛋白 (multidrug resistance- associated protein， MRP)基因及 P-糖蛋白 (P- glycoprotein, P- gp)在恶性淋巴瘤 (malignant lymphomas， ML)中的表达与化疗疗效、临床耐药的关系。方法：应用半定量逆转录多聚酶链反应 (reverse transcriptase polymerase chain reaction， RT- PCR)和流式细胞术（ flow cytometry, FCM）检测了 46例 ML患者 MRP和 P- gp的表达水平。结果：复发患者 P- gp表达水平与阳性率均高于初治患者（ P< 0.001） ,而 MRP基因表达水平与阳性率在复发与初治患者间无显著性差异 (P >0.05)。 P- gp表达阳性患者的化疗有效率 (26.67％ )明显低于 P- gp表达阴性患者 (83.87％ )(P< 0.001)，而 MRP基因表达阳性患者与阴性患者的化疗有效率无差异 (P >0.05)。相关分析显示， MRP基因表达与 P- gp表达之间无明显相关性（ r=0.0818,P >0.05）。结论： P- gp表达与恶性淋巴瘤多药耐药相关，是其临床耐药的主要机制，而 MRP基因表达与化疗疗效未见相关。
Objective: To investigate the expression of multidrug resistance-associated protein (MRP) and P-glycoprotein (P-gp) in malignant lymphomas (ML) and the efficacy of chemotherapy. The relationship between clinical drug resistance. METHODS: Reverse transcriptase polymerase chain reaction (RT-PCR) and flow cytometry (FCM) were used to detect the expression of MRP and P-gp in 46 patients with ML. Results: The expression and positive rate of P-gp in relapsed patients were higher than those in untreated patients (P<0.001). There was no significant difference in the expression and positive rate of MRP between relapsed and untreated patients (P > 0.05). The effective rate of chemotherapy in patients with positive expression of P-gp (26.67%) was significantly lower than that in patients with negative expression of P-gp (83.87%) (P<0.001). There was no difference in chemotherapy efficacy between positive patients with MRP gene expression and negative patients (P). >0.05). Correlation analysis showed no significant correlation between MRP gene expression and P-gp expression (r = 0.0818, P > 0.05). Conclusion: The expression of P-gp is related to the multidrug resistance of malignant lymphoma, which is the main mechanism of its drug resistance. However, there is no correlation between the expression of MRP gene and the efficacy of chemotherapy.